IL17A and infection: To determine if IL-17A participates in the pulmonary damage induced by the highly virulent M. bovis strain 04–303, infected mice were treated with 25 μg of IL-17A neutralizing antibodies (R&D Systems, Minneapolis, MN, USA; MAB421) or isotype control antibodies (R&D Systems; MAB006), directly administered to the lung by endotracheal instillation every other day from Days 13 to 19 post-infection, just before the development of pulmonary necrosis started (Fig 5).